Eli Lilly Invests US$3 billion to Expand Manufacturing Facility in Wisconsin, USA
Introduction:
Eli Lilly plans to invest US$3 billion for the expansion of its manufacturing facility in Wisconsin, USA.
Features:
The expanded facility will specialise in manufacturing injectable medicines, device assembly, and packaging for a variety of therapeutic areas.
The recent acquisition, expansion, and additional land purchases, along with the adjacent warehouse, bring the total planned investment in Wisconsin to US$4 billion.
The site will integrate advanced automation technologies, including guided vehicles, robotics, and production equipment, to accelerate medicine production. Digital automation will be embedded across operations, from data management to production processes, enhancing efficiency and accuracy while allowing employees to focus on delivering safe, high-quality medicines.
The expansion will create numerous highly skilled positions, including roles for operators, technicians, engineers, and scientists. Additionally, the construction phase is expected to generate over 2,000 jobs.
Construction for the expanded facility is slated to begin next year, marking a significant step in a global manufacturing growth strategy aimed at serving more patients who rely on these medicines.
This project is projected to add 750 highly skilled jobs to the existing workforce of over 100 at this location.
Specifications:
| Name : | Eli Lilly |
| Type : | Expansion |
| Budget : | US$3 billion |
